| Trial ID: | L0412 |
| Source ID: | NCT00132431
|
| Associated Drug: |
Sensipar
|
| Title: |
START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Kidney Disease|Secondary Hyperparathyroidism|Chronic Kidney Disease
|
| Interventions: |
DRUG: Sensipar
|
| Outcome Measures: |
Primary: Proportion of subjects with a mean bio-intact parathyroid hormone (biPTH) >/= 80 pg/mL and </= 160 pg/mL (comparable to K/DOQI Guideline target range for intact parathyroid hormone [iPTH] of >/= 150 pg/mL and </= 300 pg/mL) during the assessment phase | Secondary: Proportion of subjects with mean calcium-phosphorus product (Ca x P) < 55 mg²/dL² during the assessment phase
|
| Sponsor/Collaborators: |
Sponsor: Amgen
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
300
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC
|
| Start Date: |
2004-07
|
| Completion Date: |
2005-07
|
| Results First Posted: |
|
| Last Update Posted: |
2009-02-13
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00132431
|
